SCHEMBL525976

SCHEMBL525976

O=C(O)c1cnc(Nc2ccc(Cl)cn2)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.58
NPC1 O15118 6/20 0.51
RAB9A P51151 6/20 0.51
MAPT P10636 5/20 0.51
FFAR2 O15552 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 6/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
KDM4E B2RXH2 3/20 0.46
PTK2 Q05397 1/20 0.46
STAT3 P40763 1/20 0.46
HTT P42858 3/20 0.46
MAPK13 O15264 3/20 0.46
MAPK12 P53778 3/20 0.46
MAPK11 Q15759 3/20 0.46
MAPK14 Q16539 3/20 0.46
LMNA P02545 2/20 0.46
PRNP P04156 1/20 0.46
NFKB1 P19838 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3629901 0.82 RAB9A (0.68) NPC1RAB9AMAPTFFAR2SMN1; SMN2
SCHEMBL525917 0.80 RAB9A (0.50) KDRNPC1RAB9AMAPTFFAR2
SCHEMBL31039816 0.78 LCK (0.63) KDRNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL4254787 0.78 LCK (0.63) KDRNPC1RAB9AMAPTSMN1; SMN2
SCHEMBL19390260 0.78 LCK (0.72) MAPK13MAPK12MAPK11MAPK14LCK
SCHEMBL19205380 0.77 LCK (0.43) KDRNPC1RAB9AMAPTFFAR2
SCHEMBL774820 0.77 LCK (0.71) MAPK13MAPK12MAPK11MAPK14LCK
SCHEMBL775173 0.76 LCK (0.79) MAPK13MAPK12MAPK11MAPK14LCK
SCHEMBL525280 0.74 MEN1 (0.56) KDRNPC1RAB9AMAPTL3MBTL1
SCHEMBL7237283 0.73 KDR (1.00) KDRLCKSLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513430-B2 Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-20 US claimed
WO-2012015715-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-02-02 WO claimed
US-8513430-B2 Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-20 US disclosed
WO-2012015715-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-02-02 WO disclosed
US-20120029029-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029029-A1 SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS HSD11B1, HSD11B2, HSD3B1 KDR 4548/4885NPC1 205/4885RAB9A 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.